)
)
PCI Biotech Investor Relations Material
Latest events
Q2 2024
PCI Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from PCI Biotech Holding
Access all reports
Segment Data
Access more data
R&D expenses by
Category
Clinical studies
Pre-clinical studies
Patents
CMC and equipment
Expenses by
Financials
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's proprietary PCI technology targets tumors by non-invasively targeting PECAM-1 receptors on tumor blood vessels using light-activated prodrugs. It has been granted patent protection in the United States, European Union, and certain other jurisdictions for certain uses of its technologies and products.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
PCIB
Country
🇳🇴 Norway